399 reports of this reaction
1.9% of all GRANISETRON reports
#12 most reported adverse reaction
PRODUCT ADHESION ISSUE is the #12 most commonly reported adverse reaction for GRANISETRON, manufactured by Cumberland Pharmaceuticals Inc.. There are 399 FDA adverse event reports linking GRANISETRON to PRODUCT ADHESION ISSUE. This represents approximately 1.9% of all 21,280 adverse event reports for this drug.
Patients taking GRANISETRON who experience product adhesion issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT ADHESION ISSUE is a less commonly reported adverse event for GRANISETRON, but still significant enough to appear in the safety profile.
In addition to product adhesion issue, the following adverse reactions have been reported for GRANISETRON:
The following drugs have also been linked to product adhesion issue in FDA adverse event reports:
PRODUCT ADHESION ISSUE has been reported as an adverse event in 399 FDA reports for GRANISETRON. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT ADHESION ISSUE accounts for approximately 1.9% of all adverse event reports for GRANISETRON, making it a notable side effect.
If you experience product adhesion issue while taking GRANISETRON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.